Sinovac Biotech Ltd's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Sinovac Biotech Ltd's ROA in the fourth quarter of 2025?
Sinovac Biotech Ltd recorded a cumulative net loss of $-199 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -2.23%.

However, within the Healthcare sector 272 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 3239.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	82.23 %	-29.42 %	-29.42 %	-29.42 %	-69.45 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-199	41	41	41	41
Return On Assets (TTM)	-2.23 %	0.51 %	0.46 %	0.41 %	0.38 %
SVA's Total Ranking	# 3239	#	#	#	# 2906
Total Assets (TTM) in million	8,542	9,054	9,054	9,054	4,687
Seq. Total Assets Change	-5.66 %	0 %	0 %	93.16 %	-63.46 %
Seq. Net Income Change	-	-	-	-	-

SVA's 5 Years Annual ROA >> Back to SVA Management Effectiveness >> Compare SVA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 98
Sector	# 273
Overall	# 3213

Return On Assets Statistics
High	Average	Low
84.25 %	8.65 %	-8.98 %
(Dec 31 2021)		(Dec 31 2012)

Financial Statements
Sinovac Biotech Ltd's Assets	$ 8,542 million	SVA's Balance sheet
Sinovac Biotech Ltd's Income	$ -199 million	Quarterly SVA's Income Statement
SVA's Income by Division		See SVA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	93.16 %	33.58 %	-36.33 %	-58.41 %	830.43 %
Total Assets in million	9,054	4,687	3,509	5,511	13,250
Y / Y Net Income Change	-	-	-	-	7524.93 %
Net Income in million	-199	41	-121	-60	14,120
Annual Return On Assets	-2.2 %	0.87 %	-3.44 %	-1.09 %	106.56 %

SVA's 5 Years Annual ROA >> Back to SVA Management Effectiveness >> Compare SVA ROA to its Competitors

More Return On Assets Ratios
SVA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SVA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SVA's Competitors
Subscribers only: Roa for Sinovac Biotech Ltd's Suppliers
Subscribers only: Return On Assets for SVA's Customers

You may also want to know
SVA's Roi	SVA's Inventory Turnover Ratio	SVA's Growth Rates	SVA's Dividend Comparisons
	SVA's Profitability Ratios	SVA's Asset Turnover Ratio	SVA's Dividend Growth
SVA's Roe	SVA's Valuation Ratios	SVA's Financial Strength Ratios	SVA's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-16T10:47:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.